id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-D-1319-0010,FDA,FDA-2013-D-1319,Pulmonary Tuberculosis: Developing Drugs for Treatment; Guidance for Industry; Draft Guidance,Other,Guidance,2022-12-15T05:00:00Z,2022,12,2022-12-15T05:00:00Z,2023-02-14T04:59:59Z,2024-11-07T00:45:11Z,,1,0,0900006485539578
FDA-2013-D-1319-0009,FDA,FDA-2013-D-1319,Pulmonary Tuberculosis: Developing Drugs for Treatment; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2022-12-15T05:00:00Z,2022,12,,,2022-12-15T15:05:52Z,2022-27186,0,0,090000648553845d
FDA-2013-D-1319-0002,FDA,FDA-2013-D-1319,Guidance for Industry Pulmonary Tuberculosis Developing Drugs for Treatment,Other,Guidance,2013-11-10T05:00:00Z,2013,11,2013-11-10T05:00:00Z,,2022-12-15T15:01:24Z,,0,0,09000064814755f7
FDA-2013-D-1319-0001,FDA,FDA-2013-D-1319,Draft Guidance for Industry on Pulmonary Tuberculosis: Developing Drugs for Treatment; Availability,Notice,Notice of Availability,2013-11-06T05:00:00Z,2013,11,2013-11-06T05:00:00Z,2014-02-05T04:59:59Z,2020-07-28T15:22:09Z,2013-26549,0,0,09000064814724b0